CELGENE CORP (CELG) Stock News
NASDAQ:CELG - Nasdaq -
CELG Latest News, Press Relases and Analysis
Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug
Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors with losses in excess of $100,000 that they have until December 6, 2021...
Mentions: BMY
BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
/PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have...
Mentions: BMY
The Typical Unicorn Founder Started Their Business at 34
New research undercuts the perception that creating successful companies is a young person’s game.
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
/PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Bristol-Myers Squibb Company ("BMS" or "the...
Mentions: BMY
BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 6, 2021 to file lead plaintiff...
Mentions: BMY
BRISTOL MYERS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
/PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have...
Mentions: BMY
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
/PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Bristol-Myers Squibb Company ("BMS" or "the...
Mentions: BMY
BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 6, 2021 to file lead plaintiff...
Mentions: BMY
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bristol-Myers Squibb...
Mentions: BMY
Glaxo-Backed Lyell Immunopharma Wobbles in Trading Debut
Lyell Immunopharma Inc., a cancer drug developer backed by GlaxoSmithKline Plc and Celgene Corp., seesawed in its trading debut after raising $425 million in an initial public offering.
JPMorgan Hires Citi’s Chris Gartin for Health-Care Deals
JPMorgan Chase & Co. has hired Chris Gartin as a managing director in its health-care investment banking group, according to people familiar with the matter.
Bristol Myers Deal-Linked Derivative Surges on Inspection Hopes
The deal sweetener Bristol Myers Squibb Co. offered as a part of its Celgene Corp. purchase spiked as traders positioned ahead of a key year-end deadline and shared optimism related to a needed regulatory inspection.
Mentions: BMY
Bristol Myers CVR Dealt Blow as Key Drug Faces Approval Hurdle
Bristol-Myers Squibb Co.’s announcement that U.S. regulators weren’t able to meet a targeted decision deadline for a lymphoma cell therapy dealt a blow to investors as hopes for a deal sweetener for its purchase of Celgene Corp. faced more uncertainty after a rocky month.
All-or-Nothing Bet on Bristol Drugs Goes Sour as FDA Reviews Lag
The deal sweetener that Bristol Myers Squibb Co. offered as a part of its bid to buy Celgene Corp. plunged after management said U.S. regulators have not scheduled an inspection of a facility that is key for investors to get the $9 all-or-nothing payment.
Mentions: BLUE
Cory Booker Defeats Trump Loyalist for Second Senate Term
Cory Booker, the former mayor of New Jersey’s largest city and onetime Democratic presidential candidate, scored a second U.S. Senate term over a Republican who had raised scant campaign cash and downplayed the novel coronavirus.
Surge in Drug Prices Tied to Revenue, Million-Dollar Bonuses
The price of Celgene Corp’s cancer treatment Revlimid, the second best seller among U.S. drugs, more than tripled since 2005 to $719 per pill as company executives pushed to meet revenue projections tied to their million-dollar bonuses.
Bristol Myers CVR Falls as FDA Jitters Overshadow Huge Potential
Bristol Myers Squibb Co.’s comments that U.S. regulators still haven’t planned to inspect a facility that makes one of its experimental cancer drugs overshadowed news that a filing for another one of its cancer treatments with Bluebird Bio Inc. was accepted for review by the Food and Drug Administration.
Biotech IPO Nkarta triples in debut (NASDAQ:NKTX)
Nkarta (NASDAQ:NKTX) had a big IPO, upsizing the number of shares sold to 14M from 10M. It also priced at $18 vs.
AstraZeneca contacted Gilead over potential megamerger
Britain's AstraZeneca has approached U.S. rival Gilead Sciences about a possible merger to form one the world's largest drug companies.
Amgen Sales Beat Estimates as Otezla Tested for Covid Treatment
Amgen Inc., maker of the blockbuster arthritis treatment Enbrel, saw sales increase in the first quarter as newer medications began to offset declining older drugs threatened by biosimilars.
FDA OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept
Acceleron Pharma (NASDAQ:XLRN) and collaboration partner Bristol-Myers Squibb (NYSE:BMY) announce the FDA nod for Reblozyl (luspatercept-aamt) for the treatment of anemia in certain adult patients wit
FDA's OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept
Acceleron Pharma (NASDAQ:XLRN) and collaboration partner Bristol-Myers Squibb (NYSE:BMY) announce the FDA nod for Reblozyl (luspatercept-aamt) for the treatment of anemia in certain adult patients wit
Celgene CVR holders near finish line with bb2121 filing in U.S.
Bristol-Myers Squibb (NYSE:BMY) and collaboration partner bluebird bio (NASDAQ:BLUE) announce the filing of a U.S. marketing application for idecabtagene vicleucel (bb2121) for the treatment of adult
European advisory group backs Celgene's ozanimod for type of multiple sclerosis
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Celgene's (CELG) Zeposia (ozanimod) for the treatment of adults with relapsing remitting mul
Mentions: BMY
BeiGene reports Abraxane shortage in China
BeiGene (NASDAQ:BGNE) announces a supply disruption in Abraxane (nanoparticle albumin-bound paclitaxel) due to the suspension of importation instituted by the China National Medical Products Administr
All-or-Nothing Bet on New Bristol Myers Drugs Faces First Test
An upcoming U.S. regulatory decision for Bristol Myers Squibb Co.’s multiple sclerosis treatment marks the first of three key milestones that will dictate the fate of its all-or-nothing payment to former Celgene Corp. investors.
Gilead an acquisition target? Deep pockets required
Jefferies' Michael Yee says investors believe that Gilead Sciences (GILD +0.6%) is an acquisition target considering its near-term share performance (at the same level as three years ago with some vol
Celgene withdraws enasidenib application in Europe
Novartis (NYSE:NVS) unit Celgene (NASDAQ:CELG) has withdrawn its marketing application in Europe for Idhifa (enasidenib) for the treatment of adults with acute myeloid leukemia (AML).The compa
Mentions: NVS
Broken U.S. System Has Pharma on Edge Even as Stocks Hit Highs
Once-untreatable cancers and rare diseases are being vanquished. Medical breakthroughs have put Ebola and HIV on the back foot, even as new viruses emerge. Drug stocks are near record highs after a decade of gains.